Equities.com Initiates Research Coverage of Harvard Bioscience Inc. (HBIO)

Press Releases |

Equities.com, Inc., the leading online financial media organization and social community for investors, companies, and advisors, has announced today that the Equities.com Independent Research Group (EIR) has initiated coverage on Harvard Bioscience Inc. (HBIO) .

Harvard Bioscience is a global developer that manufactures and markets a broad range of specialized products. Our primary focus is scientific instruments used to advance life science and research.

Download the full report, which includes the one-year price target, probability of success, and more at http://www.equities.com/research (price: $49).

EIR provides independent investment research reports that focus on comprehensive analysis of compelling small-cap companies who lack traditional Wall Street coverage, while possessing characteristics of undervalued opportunities and favorable prospects for growth, based on a combination of fundamental, technical and quantitative factors. The coverage universe focuses on small-cap companies ranging from $200 million to $2 billion in Market Capitalization.

All reports are prepared by Equities.com’s analysts and do not represent the views of the companies covered nor are these research reports paid for by the companies in any way.

Harvard Bioscience Inc. Coverage Highlights



  • HBIO is a stable company with a strong history and is poised to grow.
  • The company has taken significant steps to increase efficiency and has made smart acquisitions.
  • The medical supply business has a high growth rate, which is projected to continue.
  • Returns are normally distributed and follow a more predictable path.
  • The company is extremely solvent and exhibits no cash problems.

Download the full HBIO report, which includes the one-year price target, probability of success, and more at http://www.equities.com/research (price: $49).

About Equities.com, Inc.

Equities.com is an online financial media organization and social community for self-directed investors, public and private companies, market experts, and professional service providers across the global capital markets. Equities.com is the only social investing site that brings together professionals and retail investors under one platform. Registered members can leverage our market-leading commentary and content curation.

Go to http://www.equities.com/community/register to become a member.

Disclaimer

The information on equities.com is for information only and we do not provide investment advice to our members or readers. To read our full disclosure, please go to: http://www.equities.com/disclaimerwhich we incorporate into this press release.

Equities.com, Inc.
Info@equities.com

(888) 207-0086

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
HBIO Harvard Bioscience Inc. 2.95 0.05 1.72 40,383 Trade

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Mesa-Marshall 2 Well Project

MESA Resources ("MESA") is sponsoring the development of the two well direct drilling project -- "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development of…

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…